Therapeutic developers are increasingly rebuilding their workflows around AI to bring drugs to patients faster.

A Study shows mutation-resistant antibodies with 269×affinity, a proof point for CEPI’s 100 Days Mission and closing ...

The Phase 1 study is a randomized, double-blind, placebo-controlled, dose-escalation trial carried out in China, designed to evaluate the safety, tolerability, pharmacokinetics (PK), and ...

Now, with its new AI-generated arsenal of porosome-targeted peptides and small molecules, the company has expanded emphasis on indications like Parkinson’s disease, Huntington’s disease, and others, ...

Overview Artificial intelligence seems to be transforming drug discovery in 2026, enabling faster molecule design, smarter clinical trials, and reduced R&D ...

Liquid AI and Insilico Medicine today announced a partnership that creates lightweight scientific foundation models for ...

"Dosing the first patient in Phase III represents a major milestone for MDR-001 and for AI-enabled drug development," said Zhangming Niu, Founder and Chief Executive Officer of MindRank. "We believe ...

Researchers will screen 700+ wild yeast strains to build a genomics database and identify species that turn waste into valuable industrial products.

Cambridge ag-biotech Bindbridge has raised $3.8m to develop AI-designed molecular glues for next-generation herbicides and ...

Multi-year partnership will utilize Iambic’s broad suite of AI drug discovery technologies and wet lab capabilities to advance collaboration programs initially in Takeda’s Oncology and ...

MindRank doses first patient in phase III clinical trial of AI-designed oral GLP-1 receptor agonist, MDR-001: Shanghai Saturday, February 28, 2026, 18:00 Hrs [IST] MindRank, a cli ...